Endo Subsidiary to Help Manufacture Novavax’s COVID-19 Vaccine

Endo International’s subsidiary Par Sterile Products has entered into an agreement with Novavax under which Par will provide fill-and-finish manufacturing of Novavax’s COVID-19 vaccine candidate in Rochester, Mich.

Par will manufacture NVX-CoV2373 for Novavax’s upcoming phase 3 trial of the vaccine in the U.S. and will also manufacture the vaccine for commercial distribution in the U.S. Financial terms of the agreement were not disclosed.

Novavax began a phase 3 trial of NVX-CoV2373 in the UK on Thursday, evaluating the vaccine against a placebo in 10,000 volunteers.